SCHEMBL16020309

SCHEMBL16020309

CCc1cnc(OC)c(NS(=O)(=O)c2cccc(C(=O)O)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.53
▸ ACLY P53396 2/20 0.53
▸ KDM4E B2RXH2 1/20 0.49
▸ TSHR P16473 1/20 0.49
▸ PTK2B Q14289 1/20 0.49
▸ CCR2 P41597 1/20 0.48
▸ PIK3C2B O00750 1/20 0.48
▸ PIK3C2G O75747 1/20 0.48
▸ RAB9A P51151 1/20 0.48
▸ KMT2A Q03164 3/20 0.48
▸ AKR1C3 P42330 2/20 0.48
▸ MEN1 O00255 2/20 0.48
▸ METAP2 P50579 1/20 0.48
▸ SLC40A1 Q9NP59 1/20 0.47
▸ PIK3CG P48736 1/20 0.47
▸ HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24139765 0.93 SLC40A1 (0.56) ALDH1A1ACLYKMT2AMEN1METAP2
SCHEMBL24139910 0.92 ALDH1A1 (0.52) ALDH1A1ACLYKDM4ETSHRPTK2B
SCHEMBL24137459 0.89 SLC40A1 (0.45) ALDH1A1ACLYKDM4EKMT2AMEN1
SCHEMBL16020322 0.89 KDM4E (0.47) ALDH1A1ACLYKDM4ETSHRPTK2B
SCHEMBL18136984 0.86 KDM4E (0.52) ALDH1A1ACLYKDM4ETSHRPTK2B
SCHEMBL13975439 0.86 ACLY (0.55) ALDH1A1ACLYKDM4ETSHRPTK2B
SCHEMBL15652812 0.85 ACLY (0.53) ALDH1A1ACLYKDM4ETSHRPTK2B
SCHEMBL24139845 0.85 ACLY (0.54) ALDH1A1ACLYKDM4ETSHRPTK2B
SCHEMBL24139854 0.85 KDM4E (0.57) ALDH1A1ACLYKDM4ETSHRPTK2B
SCHEMBL24139938 0.84 ACLY (0.52) ALDH1A1ACLYKDM4ETSHRPTK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2710018-B1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2021-12-29 — — EP disclosed
US-9808466-B2 Macrocyclic compounds as protein kinase inhibitors FUNDACIÓN CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III 2017-11-07 — — US disclosed
US-20160296528-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS Fundación Del Sector Público Estatal Centro Nacional De Investigaciones Oncológicas Carlos III (F.S.P. CNIO) (ES) 2016-10-13 — — US disclosed
US-20140256717-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS CENTRO NACIONAL DE INVESTIGACIONES ONCOLÓGICAS (CNIO) (ES) 2014-09-11 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256717-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS PIM1, PIM3, PIM2 ALDH1A1 4625/4885ACLY 1225/4885KDM4E 613/4885
US-20160296528-A1 MACROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS PIM1, PIM3, PIM2 ALDH1A1 4625/4885ACLY 1225/4885KDM4E 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback